Novo Nordisk, which manufactures weight-loss drug Wegovy and diabetes medication Ozempic, has asked the US authorities to ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

The global weight loss and obesity management market is set to experience remarkable expansion in the coming decade. With new ...

Gubra’s once-weekly obesity candidate was tied to 3% weight loss during ... a burgeoning landscape that includes Novo Nordisk ...

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...

No adequate supply? Semaglutide (GLP-1) weight-loss drug Wegovy, made by pharmaceutical company Novo Nordisk. (Photo: James ...

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...